Description

NativeMed GLP-1 Program Overview 2026: Pricing, Process, Compounded Semaglutide vs Tirzepatide Considerations

NativeMed is a telehealth platform, a network of independently licensed prescribers, and a group of partner pharmacies working together to deliver compounded GLP-1 medication to patients across the United States. Those are three separate entities, and understanding where each one’s responsibility begins and ends is the first thing anyone researching this program should know before signing up.

The platform itself, operated by NativeMed LLC, builds and hosts the questionnaire, manages billing, and coordinates the overall patient experience. The prescribers are independently licensed clinicians, such as nurse practitioners, who review each patient’s intake information and decide whether a prescription is appropriate. The pharmacies are separate, state-licensed compounding facilities responsible for preparing and shipping the actual medication. NativeMed does not manufacture or formulate any medication itself; it connects patients to the clinicians and pharmacies that do.

This distinction matters because compounded semaglutide and compounded tirzepatide, the two flagship offerings in the NativeMed program, are not FDA-approved finished drug products. They are patient-specific preparations made by licensed compounding pharmacies under a physician’s prescription. That is a legally recognized practice in the United States, but it is a meaningfully different regulatory category than an FDA-approved medication like Ozempic, Wegovy, Mounjaro, or Zepbound, and it is worth repeating throughout this overview so readers do not conflate the two.

Understanding GLP-1 and GIP Receptor Agonists

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications originally developed to manage type 2 diabetes before their weight-management effects made them one of the most sought-after drug categories in the country. They work by mimicking a naturally occurring gut hormone that slows stomach emptying, increases feelings of fullness, and helps regulate blood sugar. Semaglutide, the active ingredient in both compounded products like the one NativeMed offers and FDA-approved brand-name products, is a single-receptor GLP-1 agonist.

Tirzepatide takes this a step further by acting on two receptors instead of one: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism is why tirzepatide is sometimes associated with more pronounced weight-loss outcomes in published clinical research on the FDA-approved versions of the drug, though individual results vary widely and compounded formulations have not undergone the same large-scale clinical trials as their brand-name counterparts.

It’s worth being precise here: the clinical research demonstrating GLP-1 and GIP effectiveness was largely conducted using the FDA-approved finished products, not compounded versions. Compounded semaglutide and tirzepatide use the same active pharmaceutical ingredient, but the compounded product itself, as a manufactured item, has not been through the FDA’s own approval process. That distinction is central to understanding what a service like NativeMed is, and is not, offering.

What NativeMed Actually Offers

NativeMed markets itself primarily as a weight-loss program built around two compounded GLP-1 medications: semaglutide and tirzepatide. Both are delivered as weekly at-home injections, and both are positioned as lower-cost alternatives to brand-name GLP-1 drugs for patients who qualify after a clinical intake process.

Beyond weight management, the site also lists a small number of adjacent products, including NAD+ injections marketed for cellular energy support, and generic prescription medications for erectile dysfunction and sleep, specifically sildenafil (a generic form of Viagra), tadalafil (a generic form of Cialis), and trazodone (a generic form of Oleptro). These are presented as separate, individually priced products rather than part of the core weight-loss program, and each still requires its own qualifying questionnaire and prescriber approval.

How the Process Works

NativeMed describes a three-step intake process that mirrors the structure used across most direct-to-consumer telehealth platforms:

1. Complete a free online questionnaire, which the company states takes about three minutes and is reviewed within roughly five minutes.
2. A licensed prescriber reviews the intake information and determines whether compounded GLP-1 medication, or another requested product, is clinically appropriate for that patient.
3. If approved, the prescription is routed to a partner pharmacy, which prepares and ships the medication, typically arriving within one to three days depending on the source consulted.

No in-person visit is required at any point in this process. The entire consultation happens through the online questionnaire and, per the company’s own FAQ, a telehealth appointment with the assigned provider.

The questionnaire itself is designed to capture the same categories of information a provider would ask about during an in-person weight-management visit: current weight and goal weight, relevant medical history, current medications, prior experience with GLP-1 therapy, and any conditions that might make compounded GLP-1 treatment inappropriate. That last part matters more than it might seem. A responsible telehealth intake process exists specifically to screen out patients for whom this treatment would not be safe, not simply to process every applicant into a paying customer. Being thorough and honest on the intake form is the single most important thing a prospective patient can do to make sure the process works as intended.

Once approved, the prescription itself does not go to a retail pharmacy counter. It is routed directly to one of NativeMed’s partner compounding pharmacies, which prepares the patient-specific formulation and ships it, according to the company, with temperature-appropriate packaging given that GLP-1 injectables are sensitive to heat exposure during transit. Patients should inspect any shipment for signs of temperature exposure or damage before use and contact support if anything looks off, which is consistent with general handling guidance for injectable medications shipped directly to a home address.

Who Is Behind the Prescriptions

NativeMed’s publicly listed prescriber network includes at least one advanced practice registered nurse based in Miami, Florida, operating under an active APRN license. Pharmacy fulfillment is handled through a partner pharmacy location listed at an address in Medley, Florida, a common hub for compounding and fulfillment operations serving multiple telehealth brands. Independent third-party reviews of the program describe the compounded medications as being prepared through licensed 503A compounding pharmacies, which is the standard regulatory pathway for patient-specific compounded prescriptions in the U.S.

Compounded Semaglutide vs Compounded Tirzepatide: Pricing Breakdown

As of this writing, NativeMed lists its two core GLP-1 products at the following starting prices:

• Compounded Semaglutide (GLP-1): listed at a reduced starting price of $149, down from a stated regular price of $299.
• Compounded Tirzepatide (GLP-1/GIP): listed at a reduced starting price of $183, down from a stated regular price of $399.

Tirzepatide targets both the GLP-1 and GIP receptors, which is the same dual-agonist mechanism used in brand-name tirzepatide products, while semaglutide is a single-receptor GLP-1 agonist. The choice between the two is a clinical decision that should be made with the prescribing provider based on a patient’s history, prior response to GLP-1 therapy, and tolerance, not on price alone. Both are billed as weekly injections administered at home.

The company states that its compounded pricing runs up to 85% below retail prices for FDA-approved GLP-1 medications. That is a comparative claim rather than a controlled clinical comparison, and readers should treat it as the company’s own pricing position rather than a third-party verified benchmark.

Other Products on the Platform

NativeMed also lists several non-GLP-1 products at the following starting prices:

• NAD+ Injection: starting at $159, discounted from $199.
• Generic Sildenafil (for Viagra): starting at $5.
• Generic Tadalafil (for Cialis): starting at $5.
• Generic Trazodone (for Oleptro): starting at $30.

Each of these still requires the same intake-and-approval process described above; they are not sold without a prescriber review.

Insurance, Payment, and Ongoing Costs

NativeMed does not accept health insurance for its compounded medications, and it states this plainly in its own FAQ. Patients are solely responsible for the cost of services rendered. The company does, however, accept Health Savings Account (HSA) and Flexible Spending Account (FSA) payment for eligible patients, which can offset some of the out-of-pocket cost depending on a patient’s specific plan rules.

There is no membership fee layered on top of the medication cost based on the company’s own pricing pages, and the site advertises free or discounted overnight shipping on qualifying orders, though shipping windows described across the site and its FAQ range from one to three days depending on the page referenced.

Cancellation and Refund Policy

According to NativeMed’s own FAQ, there are no long-term contracts and no cancellation fees. Patients can stop at any point, and the company states that patients are only responsible for medication that has already shipped. This is a fairly standard cancellation structure for direct-pay telehealth weight-loss platforms, but patients should confirm the specific terms in writing before starting treatment, since exact refund conditions can vary by order status and by state.

What Compounding Means, and Why the Distinction Matters

Drug compounding is a legal, long-established practice in the United States. It involves a licensed pharmacy combining, mixing, or altering ingredients to create a medication tailored to an individual patient’s prescription, often used when a commercially manufactured drug is not available, not tolerated, or not accessible at a needed dose. NativeMed states that it works exclusively with state-licensed U.S. compounding pharmacies that are expected to meet regulatory standards for quality and safety.

What compounding does not mean is FDA approval of the finished product. The FDA does not review or approve individual compounded preparations for safety and efficacy the way it does with manufactured drugs like brand-name semaglutide or tirzepatide products. NativeMed’s own site includes a standard disclosure stating that its statements have not been evaluated by the FDA and that its products are not intended to diagnose, treat, cure, or prevent any disease, which is consistent with how compounded GLP-1 providers are expected to present this information.

How NativeMed Fits Into the Broader Compounded GLP-1 Market

NativeMed operates in a crowded field. Compounded GLP-1 telehealth has grown rapidly over the past few years, driven largely by two factors: persistent supply shortages of brand-name semaglutide and tirzepatide products, and the significant price gap between compounded and brand-name options for patients paying out of pocket. Dozens of platforms now offer some version of the same core service NativeMed does: an online questionnaire, a licensed prescriber network, and a partner compounding pharmacy.

What differentiates one provider from another in this space usually comes down to a handful of concrete factors rather than marketing language: transparency about pricing before checkout, the specific compounding pharmacies used and whether they are 503A or 503B facilities, how clearly cancellation and refund terms are spelled out, and how responsive customer support is when something goes wrong with a shipment. Based on the company’s own published pages and third-party review sources, NativeMed publishes its starting prices directly on its product pages rather than hiding them behind the questionnaire, states its cancellation policy in plain language, and has LegitScript approval, which is one of the more commonly referenced verification standards in this specific market.

That said, “starting at” pricing is common across this entire category, and the final price a patient pays often depends on dosage tier, whether the plan is billed monthly or in a longer subscription cycle, and any add-on consultations. Prospective patients comparing NativeMed against other compounded GLP-1 providers should request a full breakdown of the total cost at their specific dose before committing, rather than assuming the advertised starting price will be the ongoing price.

Reputation and Independent Feedback

NativeMed carries LegitScript approval, a third-party pharmacy and telehealth verification credential that online pharmacies and telehealth platforms commonly use to demonstrate they meet baseline regulatory and operational standards. The company also links out to Trustpilot for customer reviews directly from its homepage.

Independent, community-sourced review platforms tracking GLP-1 telehealth providers describe generally positive experiences with NativeMed’s customer support, including responsiveness when shipping or dosing issues came up. As with any crowd-sourced review platform, individual experiences vary, and prospective patients should weigh a range of sources rather than relying on any single review.

General Safety Considerations With GLP-1 Therapy

GLP-1 and GLP-1/GIP medications, whether compounded or FDA-approved, are associated with a well-documented set of common side effects reported in clinical literature on the finished drug class, most frequently gastrointestinal in nature: nausea, diarrhea, constipation, and reduced appetite, particularly during dose initiation or increases. These effects tend to be most pronounced early in treatment and often lessen as the body adjusts, though that is not universal, and any persistent or severe symptoms should be reported to the prescribing provider promptly rather than managed independently.

Because these are prescription medications requiring an individualized clinical decision, this article is not a substitute for that evaluation. Patients with a personal or family history of certain thyroid conditions, pancreatitis, or specific gastrointestinal disorders are generally considered poor candidates for this drug class, which is exactly the kind of history an intake questionnaire and prescriber review are designed to catch. Anyone considering NativeMed, or any compounded GLP-1 provider, should disclose their complete medical history rather than only the information they think is relevant to weight loss.

Frequently Asked Questions

Does NativeMed require an in-person visit?
No. The entire process, from intake questionnaire to prescriber review to medication shipment, is designed to be completed online, according to the company’s own description of its process.

Is compounded medication the same as the FDA-approved brand-name version?
No. Compounded semaglutide and tirzepatide use the same active pharmaceutical ingredient found in brand-name products, but the compounded preparation itself is not an FDA-approved finished drug. Compounding is a legal and regulated practice, but it is a different regulatory pathway than FDA drug approval.

Does NativeMed accept insurance?
According to the company’s own FAQ, insurance is not accepted for its compounded medications, though HSA and FSA payment methods are accepted, and patients are responsible for the full cost of services.

Are there long-term contracts?
The company states there are no long-term contracts or cancellation fees, and that patients are only responsible for medication that has already shipped at the time of cancellation.

How long does shipping take?
NativeMed’s own pages describe shipping windows ranging from one to three days depending on which page is referenced, with the company also advertising free or discounted overnight shipping on qualifying orders.

Who reviews the intake questionnaire?
Independently licensed prescribers within NativeMed’s provider network, separate from the NativeMed platform itself and separate from the pharmacies that fulfill approved prescriptions.

Who This Program May Fit

Based on the structure NativeMed has published, this type of program tends to appeal to adults who want a fully virtual path to GLP-1 treatment, do not have insurance coverage for weight-loss medication, and are comfortable with the tradeoffs of compounded rather than FDA-approved finished products. It is not positioned as a replacement for in-person care for patients with complex medical histories, and anyone considering it should disclose their full medical history during intake and discuss alternatives with their prescriber, including FDA-approved options, if those are a better clinical fit.

It may be a less obvious fit for patients already stable on an FDA-approved brand-name GLP-1 medication through insurance coverage, since compounded alternatives are typically priced for the uninsured cash-pay market rather than as a direct insurance substitute. It’s also a consideration for patients who are earlier in researching GLP-1 therapy generally and want to understand the full landscape, including brand-name options, before deciding whether a compounded, direct-pay path is the right starting point. A conversation with a primary care provider, along with anything learned from a platform like NativeMed, is a reasonable way to weigh both paths before committing to either.

The Bottom Line

NativeMed sits within a well-established and increasingly competitive category of direct-pay, compounded GLP-1 telehealth providers. Its core offer, compounded semaglutide starting at $149 and compounded tirzepatide starting at $183, is priced in line with much of that category, and its process, an online questionnaire, independent prescriber review, and pharmacy-fulfilled shipping, follows the same structure used across most of its competitors. The company discloses its lack of insurance coverage, its cancellation terms, and the fact that compounded medications are not FDA-approved finished products directly on its own site, which is the kind of transparency worth looking for in this category regardless of which specific provider a patient ultimately chooses.

As with any prescription treatment, the right decision depends on an individual’s full medical history and goals, not on price or marketing alone. Anyone considering NativeMed, or any comparable compounded GLP-1 provider, should go into the intake process with complete and honest information and treat the resulting prescriber review as a genuine clinical checkpoint rather than a formality.

Key Takeaways

• NativeMed operates as a telehealth intake and coordination platform; prescribing and pharmacy fulfillment are handled by separate, independently licensed entities.
• Compounded semaglutide starts at $149 and compounded tirzepatide starts at $183, both billed as weekly at-home injections.
• Compounded medications are not FDA-approved finished drug products, even though compounding itself is a legal, regulated practice.
• Insurance is not accepted, though HSA/FSA payment is, and there are no long-term contracts or cancellation fees.
• The platform holds LegitScript approval and publishes third-party review links directly on its site.

View current NativeMed program details

Important: The statements above have not been evaluated by the Food and Drug Administration. Compounded medications discussed in this article are not FDA-approved finished drug products. This article is for informational purposes only, is not medical advice, and is not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed healthcare provider before starting any new medication or treatment program.